Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

National Healthcare (NHC) Receivables (2016 - 2025)

National Healthcare's Receivables history spans 16 years, with the latest figure at $157.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 2.22% year-over-year to $157.7 million; the TTM value through Dec 2025 reached $157.7 million, up 2.22%, while the annual FY2025 figure was $157.7 million, 2.22% up from the prior year.
  • Receivables reached $157.7 million in Q4 2025 per NHC's latest filing, up from $132.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $157.7 million in Q4 2025 to a low of $94.3 million in Q1 2021.
  • Average Receivables over 5 years is $117.6 million, with a median of $112.2 million recorded in 2021.
  • Peak YoY movement for Receivables: dropped 6.09% in 2021, then increased 29.87% in 2025.
  • A 5-year view of Receivables shows it stood at $115.0 million in 2021, then grew by 3.3% to $118.8 million in 2022, then rose by 7.38% to $127.6 million in 2023, then rose by 20.93% to $154.3 million in 2024, then increased by 2.22% to $157.7 million in 2025.
  • Per Business Quant, the three most recent readings for NHC's Receivables are $157.7 million (Q4 2025), $132.4 million (Q3 2025), and $142.1 million (Q2 2025).